News

The takeover drama of Britain's AstraZeneca by US drugs giant Pfizer has now reached British prime minister David Cameron's doorstep. In a letter to Cameron, Pfizer chief Ian C. Read tried to address concerns over the bid and said...

Pfizer Inc. has announced the election of James C. Smith to its Board of Directors, effective immediately. Mr. Smith also was appointed to the Corporate Governance and Science and Technology Committees of Pfizer's Board. Mr. Smith,...

The US crackdown on healthcare fraud is paying huge dividends to the exchequer, accounting for three quarters of the money recovered as penalties in fraud cases exposed by whistleblowers between 1987 and 2013-over $21 billion of the total $27...

Large amounts of information generated by gene expression profiling will increase implementation of data management tools Gene expression profiling can bring significant improvements to disease profiling and diagnoses based on genetic disposition. Recent technology...

Isis Earns $14 Million Milestone Payment from Biogen Idec ISIS-DMPKRx is the Second Generation 2.5 Antisense Drug to Enter the Clinic Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-DMPKRx.  Isis earned a...

On Friday, June 06, 2014, the NASDAQ Composite ended at 4,321.40, up 0.59%, the Dow Jones Industrial Average finished the day 0.52% higher at 16,924.28, and the S&P 500 closed at 1,949.44, up 0.46%. The gains were broad based...

US-based Immune Design has started dosing patients in a Phase I clinical study of LV305, an immuno-oncology investigational agent from its DCVex lentiviral vector platform to treat patients with locally advanced, relapsed, or metastatic breast cancer, melanoma, non-small cell...